Coronary percutaneous revascularization procedures

Series
Coronary interventions
Status
Published
Date
Number of report
019

Ask the expert

(we accept only company emails)

Report presents summary of reimbursement situation for number of coronary percutaneous revascularization methods. Procedures, covered in the report include:

  • Percutaneous coronary balloon angioplasty (including plain and drug-coated balloons)
  • Percutaneous coronary angioplasty with stenting using bare metal, drug-eluting and bioresorbable stents
  • Mechanical thrombectomy
  • Mechanical atherectomy

Analysis is provided for three indications: stable angina, unstable angina and acute myocardial infarction.

Day case procedures are not considered in the report. 

Report includes essential information about reimbursement and national funding, including:

  • Brief overview of reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Switzerland

It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Manufacturers of devices for coronary percutaneous revascularization include:

  • Aachen Resonance (PTCA catheter CORONARY)
  • Abbott Vascular (Coronary stent XIENCE Alpine, Coronary stent XIENCE Xpedition, Coronary stent graft GRAFTMASTER RX)
  • Accura (Coronary stent Accura Decent S, Coronary stent Decent, PTCA catheter Positsoon)
  • Acrostak (PTCA catheter ACROSS HP™, PTCA catheter GRIP™)
  • amg International (Coronary stent Pico Elite, Coronary stent ICROS, PTCA catheter ISTAR)
  • Amnis Therapeutics (Biological membrane-covered coronary stent AneugraftDx)
  • Andramed (Coronary stent AndraStent)
  • AngioScore (PTCA catheter AngioSculpt®)
  • Argon Medical (Fixed Core Straight & PTFE Coated Guidewires)
  • Arthesys (Coronary stent Cygnus II, PTCA catheter Maya)
  • Asahi Intecc (PTCA catheter Zenyte EX)
  • B. Braun (Coronary stent Coroflex® ISAR NEO, Coronary stent Coroflex® Blue Neo, PTCA catheter SeQuent® Please NEO, PTCA catheter SeQuent® Neo, PTCA catheter NSE Alpha, PTCA catheter SeQuent® Please OTW)
  • Balton (Coronary stent BIOSS, Coronary stent BIOSS EXPERT, PTCA catheter RIVER, PTCA catheter BOTTLE)
  • Bentley InnoMed (Coronary stent graft BeGraft)
  • Biomerics (PTCA Balloon catheters)
  • Biotronik (Coronary stent Magmaris, Coronary stent Orsiro, PTCA catheter Pantera LEO, PTCA catheter Pantera Pro)
  • Boston Scientific (Coronary stent Promus PREMIER™, Coronary stent ION™, PTCA catheter Apex™, PTCA catheter Emerge™)
  • Capture Vascular (Thrombectomy catheter MegaVac)
  • Cardionovum (Coronary stent Precision® series, Coronary stent Xlimus series)
  • Cardiva (Flagship XS. PTCA coronary guide)
  • Celonova (Coronary stent COBRA PzF™, Coronary stent CATANIA™)
  • Clearstream Technologies  (Coronary stent SatinFlex™, Coronary stent ClearFlex-X®, PTCA catheter NIMBUS PICO® µ, PTCA catheter Nimbus Salvo™)
  • Comed (Coronary stent Deimos™, Coronary stent Miranda™, PTCA catheter Oberon™)
  • Conic Vascular (PTCA balloon catheter NC CLEVER)
  • Control Medical Technology (Thrombectomy catheter ASPIRE)
  • Cordis (PTCA catheter EMPIRA®, PTCA catheter EMPIRA® NC)
  • Degania Silicone (Coronary stent, PTCA catheter)
  • Elixir Medical (Coronary stent DESyne®, Coronary stent DESyne® BD)
  • Endocor (Coronary stent SEQUENCE™, Coronary stent CONSTELLATION™, PTCA catheter CARDIOGLIDE™ HP, PTCA catheter CARDIOGLIDE™ CTO,Thrombectomy catheter PHANTOM 7F™, Thrombectomy catheter PHANTOM™ 5F)
  • Eucatech (Coronary stent eucaLimus, Coronary stent Ccflex, PTCA catheter eucaVI)
  • Eurocor (Coronary stent E-MAGIC PLUS, Coronary stent MAGICAL®, PTCA catheter DIOR)
  • Goodman Medical Ireland Limited (PTCA balloon Lacrosse, PTCA Y connector OKAY II)
  • HEXACATH (Coronary stent Titan Optimax, Coronary stent TITAN2, PTCA catheter Mistral SC, PTCA catheter Mistral NC)
  • IMeSI Italia (PTCA catheter Apollo Fluens, PTCA catheter Apollo HP)
  • InSitu Technologies (Coronary stent Celosia™, Coronary stent Direct-Stent®, Coronary stent graft Direct-Stent®, PTCA catheter Arriva™ PTCA)
  • InspireMD (Coronary stent Mguard, Coronary stent MGuard Prime)
  • Intelligent Kinetics (PEGASUS PTCA Balloon Catheter, ABARIS Rapamycin-Eluting Coronary Stent System, CORPAX Drug Eluting Balloon)
  • iVascular (Coronary stent Angiolite, Coronary stent Architect, Thrombectomy catheter Capturer, Coronary stent graft Prograft, PTCA catheter NC Xperience)
  • Japan Lifeline (PTCA Guide Wires, PTCA Balloon Catheters)
  • Kaneka (PTCA Balloon Catheter IKAZUCHI Zero, IKAZUCHI-Rev, IKAZUCHI X Hyp, RAIDEN3, Ryusei)
  • LVD Biotech (PTCA Guide wires)
  • Medas Inc (Coronary stent Inspire™, Coronary stent Brave™)
  • Medinol (Coronary stent NIRxcell™, PTCA catheter Assure™)
  • Merit Medical Systems (Catheter guidewire Worley™, Catheter guidewire Ostial PRO®)
  • Micro Science Medical AG (Drug Eluting PTCA Balloon Catheter MSM® DECO, BMS Stainless Steel Stent Coronary Implant System MSM® CIS BARE  (Stent))
  • MicroPort (PTCA catheter FOXTROT™ NC, PTCA catheter JIVE™)
  • Minvasys (Coronary stent Nile® Pax, Coronary stent Nile Croco®, PTCA catheter Yangtze® µ, PTCA catheter Yangzte® NC)
  • Opsens (Pressure Wire OptoWire Deux)
  • Oscor (Balloon catheters, Stent delivery systems)
  • Ostial Corporation (Flash-C PTCA balloon dilatation catheters)
  • QualiMed (PTCA Balloon catheter)
  • Rontis Medical (Coronary stent Abrax™, Coronary stent Phoenix Pico™)
  • SIS Medical (PTCA catheter TIN®, PTCA catheter BEO NC®)
  • Stentys (Coronary stent Xposition S, Coronary stent MiStent SES®)
  • STI Laser (Coronary stents)
  • Svelte Medical Systems (Coronary stent SVELTE™)
  • Terumo (Coronary stent Ultimaster®, Coronary stent Kaname®, PTCA catheter Heartrail® II, PTCA catheter Accuforce®)
  • Tokai Medical Products (Jadeite PTCA balloon catheter)
  • Translumina (Coronary stent Yukon® Choice PC, Coronary stent Yukon® Choice 4DES,  PTCA catheter Cathy N° 4)
  • Tryton Medical (Coronary stent)
  • Vitalcor (CORONARY ARTERY PERFUSION CANNULA WITH BALLOON)
  • Wellinq (Coronary stent Track, Coronary stent Pioneer, PTCA catheter Protégé, PTCA catheter Protégé NC, PTCA catheter Force NC, PTCA catheter Everest)
  • Zeus (Covered Stents)

Table of content

1.    Introduction and summary
2.    Executive summary table
3.    Contents
4.    Abbreviations
5.    Methodology
6.    Reimbursement analysis in Austria

6.1.    Overview of the reimbursement system
6.2.    Reimbursement for coronary percutaneous revascularization procedures
6.2.1.    Procedure coding
6.2.2.    Diagnosis coding
6.2.3.    Payment mechanism and reimbursement tariffs
6.2.4.    Policy considerations by the LBI-HTA
7.    Reimbursement analysis in Belgium
7.1.    Overview of the reimbursement system
7.2.    Reimbursement for coronary percutaneous revascularization procedures
7.2.1.    Procedure coding
7.2.2.    Payment mechanism and reimbursement tariffs
7.2.3.    Policy considerations 
7.2.4.    Health technology assessments by KCE 
8.    Reimbursement analysis in Denmark
8.1.    Overview of the reimbursement system
8.2.    Reimbursement for coronary percutaneous revascularization procedures
8.2.1.    Procedure coding 
8.2.2.    Diagnosis coding
8.2.3.    Payment mechanism and reimbursement tariffs
8.2.4.    Policy considerations 
9.    Reimbursement analysis in England
9.1.    Overview of the reimbursement system
9.2.    Reimbursement for coronary percutaneous revascularization procedures
9.2.1.    Procedure coding 
9.2.2.    Diagnosis coding
9.2.3.    Payment mechanism and reimbursement tariffs
9.2.4.    Policy considerations 
9.2.4.1.    Specifics of commissioning of the procedure
9.2.4.2.    Health technology assessments by NICE
10.    Reimbursement analysis in France
10.1.    Overview of the reimbursement system
10.2.    Reimbursement for coronary percutaneous revascularization procedures
10.2.1.    Procedure coding 
10.2.2.    Diagnosis coding
10.2.3.    Payment mechanism and reimbursement tariffs
10.2.4.    Policy considerations by HAS
11.    Reimbursement analysis in Germany
11.1.    Overview of the reimbursement system
11.2.    Reimbursement for coronary percutaneous revascularization procedures
11.2.1.    Procedure coding 
11.2.2.    Diagnosis coding
11.2.3.    Payment mechanism and reimbursement tariffs
11.2.4.    Policy considerations by G-BA
12.    Reimbursement analysis in Italy
12.1.    Overview of the reimbursement system
12.2.    Reimbursement for coronary percutaneous revascularization procedures
12.2.1.    Procedure coding at national level
12.2.2.    Procedure coding at regional level (Emilia-Romagna, Lombardy, Veneto regions)
12.2.3.    Diagnosis coding
12.2.4.    Payment mechanism and reimbursement tariffs at national level
12.2.5.    Payment mechanism and reimbursement tariffs at regional level
13.    Reimbursement analysis in the Netherlands
13.1.    Overview of the reimbursement system
13.2.    Reimbursement for coronary percutaneous revascularization procedures
13.2.1.    Procedure coding 
13.2.2.    Diagnosis coding
13.2.3.    Payment mechanism and reimbursement tariffs
13.2.4.    Policy considerations by Dutch Healthcare Institute (СIN)
14.    Reimbursement analysis in Norway
14.1.    Overview of the reimbursement system
14.2.    Reimbursement for coronary percutaneous revascularization procedures
14.2.1.    Procedure coding 
14.2.2.    Diagnosis coding
14.2.3.    Payment mechanism and reimbursement tariffs
14.2.4.    Policy considerations 
15.    Reimbursement analysis in Sweden
15.1.    Overview of the reimbursement system
15.2.    Reimbursement for coronary percutaneous revascularization procedures
15.2.1.    Procedure coding 
15.2.2.    Diagnosis coding
15.2.3.    Payment mechanism and reimbursement tariffs
15.2.4.    Policy considerations
16.    Reimbursement analysis in Switzerland
16.1.    Overview of the reimbursement system
16.2.    Reimbursement for coronary percutaneous revascularization procedures
16.2.1.    Procedure coding 
16.2.2.    Diagnosis coding
16.2.3.    Payment mechanism and reimbursement tariffs
16.2.4.    Policy considerations
17.    Disclaimer

28

Jun 2021

In mid-June 2021, the document "Changes and innovations in the 2022 LKF model" (Änderungen und Neuerungen in den LKF-Modellen 2022) was published. The document summarizes the most significant changes and innovations in the LKF model for inpatient and outpatient care. The newly added procedure codes concern mainly the cardiovascular, e-Health, and gastrointestinal area.

Read more

09

Jun 2021

For the first time in three years, the Institute for Quality and Efficiency in Health Care (IQWiG) received data within the framework of the early benefit assessment of new examination and treatment methods (NUB) with high-risk medical devices according to §137h of Social Code Book (SGB) V. This involves seven invasive therapeutic cardiovascular, pulmonary, neurological, gastrointestinal, and urological procedures.

Read more

26

May 2021

On May 6, 2021, the Federal Joint Committee (G-BA) announced the start of consultations about the design of three co-funded studies for cardiovascular methods in accordance with §137e SGB V.

Read more

22

Dec 2020

In November 2020, the National Institute for Health and Care Excellence (NICE) published one new interventional procedure guidance (for swallowable gastric balloon capsule for weight loss), five Medtech innovation briefings (for QuickChange Incontinence Wrap for urinary incontinence in men, Magseed for locating breast cancer lesions, Dexcom G6 for continuous glucose monitoring, and others). Also, one clinical guidance (for acute coronary syndromes) was updated.

Read more

27

Nov 2020

On October 30, 2020, the Swiss Federal Statistics Office (UFS) published the 2021 version of the procedure code (CHOP) nomenclature in French and Italian. The version in the German language was published in July 2020. The most important changes regard cardiovascular and peripheral vascular interventions.

Read more
(we accept only company emails)